Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 15/20 | 0.43 |
| ▸ | MAP2K2 | P36507 | 4/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL390459 | 0.87 | MAP2K1 (0.42) | MAP2K1MAP2K2 | |
| SCHEMBL391296 | 0.87 | MAP2K1 (0.53) | MAP2K1MAP2K2 | |
| SCHEMBL393738 | 0.82 | KCNH2 (0.44) | MAP2K1MAP2K2 | |
| SCHEMBL393737 | 0.82 | KCNH2 (0.44) | MAP2K1MAP2K2 | |
| SCHEMBL392304 | 0.80 | MAP2K1 (0.50) | MAP2K1MAP2K2 | |
| SCHEMBL392305 | 0.80 | MAP2K1 (0.50) | MAP2K1MAP2K2 | |
| SCHEMBL391362 | 0.79 | MAP2K1 (0.56) | MAP2K1MAP2K2 | |
| SCHEMBL393879 | 0.78 | MAP2K1 (0.56) | MAP2K1MAP2K2 | |
| SCHEMBL393641 | 0.78 | MAP2K1 (0.54) | MAP2K1MAP2K2 | |
| SCHEMBL394408 | 0.77 | MAP2K1 (0.52) | MAP2K1MAP2K2L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1967516-B1 | 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as MEK inhibitors for the treatment of hyperproliferative diseases | ARRAY BIOPHARMA INC (US) | 2009-11-04 | — | — | EP | disclosed |
| EP-1967516-A1 | 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as MEK inhibitors for the treatment of hyperproliferative diseases | Array Biopharma, Inc. (US) | 2008-09-10 | — | — | EP | disclosed |